ArticleNature communications2024
The CUL5 E3 ligase complex negatively regulates central signaling pathways in CD8
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
5.1field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 18 citations in OpenAlex.
- Post‑translational modification‑governed immune states in cancer immunity: Biomarker implications for checkpoint competence, tumor visibility and immunotherapy resistance (Review).International journal of oncology · 2026Review
- Post-Translational Regulation of CD8Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- CUL5 E3 ubiquitin ligase regulates the evasion of bladder cancer cells to CD8+ T cell-mediated killing by inhibiting autophagy.PLoS biology · 2026Article
- Decoding neddylation in malignancies: molecular mechanisms, biological functions, therapeutic resistance, and clinical potential.Cell death & disease · 2026Review
- Cul5: immune cell function and therapeutic potential.Frontiers in immunology · 2026Review
- CUL5-mediated ubiquitination in cancer cell therapy: context-dependent roles, molecular networks, and emerging therapeutic avenues.Frontiers in medicine · 2026Review
- Genome-wide CRISPR screens identify critical targets to enhance CAR-NK cell antitumor potency.Cancer cell · 2025Article
- Base-editing a single missense mutation in A20 enhances CAR-T cell efficacy.bioRxiv : the preprint server for biology · 2025Article
- The E3 ubiquitin ligase Cul5 regulates hematopoietic stem cell function for steady-state hematopoiesis in mice.The Journal of clinical investigation · 2025Article
- Ubiquitination in cancer: mechanisms and therapeutic opportunities.Cancer communications (London, England) · 2025Review
- A STUB1-CHIC2 complex inhibits CD8Nature immunology · 2025Article
- NEDDylation Regulates CD8+ T-cell Metabolism and Antitumor Immunity.Cancer immunology research · 2025Article
- A genome-wide association study of European advanced cancer patients treated with opioids identifies regulatory variants on chromosome 20 associated with pain intensity.European journal of pain (London, England) · 2025Article
- E3 Ligase Rbx1 Orchestrates Thymus Development and Fate Determination of αβ-γδ T Cells.Research (Washington, D.C.) · 2025Article
- Understanding TCR T cell knockout behavior using interpretable machine learning.Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing · 2025Article
- Cellular behavior analysis from live-cell imaging of TCR T cell-cancer cell interactions.bioRxiv : the preprint server for biology · 2024Article
- Ubiquitin modification in the regulation of tumor immunotherapy resistance mechanisms and potential therapeutic targets.Experimental hematology & oncology · 2024Review
- CRISPR-Cas gene knockouts to optimize engineered T cells for cancer immunotherapy.Cancer gene therapy · 2024Review
- Integrated Proteomics Reveal ALDH1A1 as an Oncogenic Driver and Regulatory Hub in Hepatocellular Carcinoma.Cancer genomics & proteomicsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Xiaofeng Liao *Vascular Biology and Therapeutic Program, Yale University School of Medicine, New Haven, CT, 06520, USA. xiaofeng.liao@yale.edu.ORCID 0000-0002-6671-4714
Wenxue Li *Department of Pharmacology, Yale University School of Medicine, New Haven, CT, 06520, USA.ORCID 0000-0002-8902-0184
Hongyue Zhou *Vascular Biology and Therapeutic Program, Yale University School of Medicine, New Haven, CT, 06520, USA.
Barani Kumar Rajendran *Vascular Biology and Therapeutic Program, Yale University School of Medicine, New Haven, CT, 06520, USA.ORCID 0000-0001-9675-7718
Ao Li *Department of Pharmacology, Yale University School of Medicine, New Haven, CT, 06520, USA.
Jingjing Ren *Department of Dermatology, Yale University School of Medicine, New Haven, CT, 06520, USA.ORCID 0000-0002-5979-7443
Yi LuanVascular Biology and Therapeutic Program, Yale University School of Medicine, New Haven, CT, 06520, USA.
David A CalderwoodDepartment of Pharmacology, Yale University School of Medicine, New Haven, CT, 06520, USA.ORCID 0000-0002-0791-4142
Benjamin TurkDepartment of Pharmacology, Yale University School of Medicine, New Haven, CT, 06520, USA.ORCID 0000-0001-9275-4069
Wenwen TangVascular Biology and Therapeutic Program, Yale University School of Medicine, New Haven, CT, 06520, USA. wenwen.tang@yale.edu.ORCID 0000-0001-9234-4385
Yansheng LiuDepartment of Pharmacology, Yale University School of Medicine, New Haven, CT, 06520, USA. yansheng.liu@yale.edu.ORCID 0000-0002-2626-3912
Dianqing WuVascular Biology and Therapeutic Program, Yale University School of Medicine, New Haven, CT, 06520, USA. dan.wu@yale.edu.ORCID 0000-0002-7342-5961
Yale University · USYale Cancer Center · US
Funding
A novel signaling mechanism for LRP5R01CA274735 · NCI · YALE UNIVERSITY · PI Dianqing Wu · 2022 to 2026
$2.7MDKK2 regulates NK activation and tumor immunityR01CA214703 · NCI · YALE UNIVERSITY · PI WU, DIANQING · 2018 to 2022
$2.5MUnderstanding proteome remodeling in aneuploidyR01GM137031 · NIGMS · YALE UNIVERSITY · PI LIU, YANSHENG · 2020 to 2024
$2.0MNCI NIH HHS R01 CA214703NCI NIH HHS R01 CA274735NIGMS NIH HHS R01 GM137031
Abstract
CD8
Indexed as
CD8-Positive T-LymphocytesCullin ProteinsUbiquitin-Protein LigasesAnimalsMiceNeoplasmsProteomicsReceptors, Antigen, T-CellSignal TransductionSuppressor of Cytokine Signaling Proteinscullin5 protein, mouseCullin ProteinsReceptors, Antigen, T-CellSuppressor of Cytokine Signaling ProteinsUbiquitin-Protein Ligases
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.